NTZ, in particular, modifies miRNA expression profiles in patients with MS (13), reducing the expression of miR-126-3p in peripheral lymphocytes (7) and increasing that of the two of the targets of this miRNA: the transcription factors POU2AF1 and Spi-B (14). Here, SPIB is linked to myeloid sarcoma.